Overview
- 26 inspections across 26 sites are on record.
- 173 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2025-02-27.
At a glance
Inspections
26
Sites
26
Observations
173
Career since
Mar 2009
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Revance Therapeutics, Inc. | 27 Feb 2025 | Human Drugs | On file |
| Jubilant HollisterStier General Partnership | 14 Jun 2024 | Human Drugs | On file |
| Genentech, Inc. | 19 Apr 2024 | Human Drugs | On file |
| Specialty Process Labs LLC | 26 Jan 2024 | Human Drugs | On file |
| Catalent Pharma Solutions LLC | 15 Dec 2022 | Human Drugs | On file |
Sites inspected
Revance Therapeutics, Inc.Newark, United States1 insp.
Jubilant HollisterStier General PartnershipKirkland, Canada1 insp.
Genentech, Inc.Hillsboro, United States1 insp.
Specialty Process Labs LLCPhoenix, United States1 insp.
Catalent Pharma Solutions LLCMorrisville, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Mindy M Chou3 shared
Jeffrey P Raimondi2 shared
Yvins Dezan2 shared
Marcus A Ray2 shared
Juanita P Versace2 shared
Margaret M Annes2 shared
Linda Thai1 shared
Crystal Monroy1 shared
Joan M Cantellops Figueroa1 shared
Jose E Melendez1 shared
Full investigator report
Get the verbatim findings behind Philip F Istafanos' 173 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site